Scleroderma associated autoantibodies - Clinical and diagnostic relevance;Sklerodermie-assoziierte autoantikörper - Klinische und diagnostische relevanz

Zeitschrift fur Rheumatologie

Volumn 65, Issue 4, 2006, Pages 279-284

  Mierau, R ^a   Genth, E ^b  

^a Labor an der Rheumaklinik Aachen   (Germany)

^b Rheumaklinik und Rheumaforschungsinstitut Aachen ^*  (Germany)

Author keywords

Autoantibodies; Diagnostics; Scleroderma; Systemic sclerosis (SSc)

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA TOPOISOMERASE; ENZYME ANTIBODY;

ANTIBODY DETECTION; CLINICAL EXAMINATION; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HEREDITY; HUMAN; IMMUNE SYSTEM; PATHOGENESIS; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; DNA-DIRECTED RNA POLYMERASES; HUMANS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 33746447826     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0067-y     Document Type: Review

References (48)

1. Akimoto S, Ishikawa O, Takagi H, Miyachi Y (1998) Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 13: 897-901
2. Arbuckle MR, McClain MT, Rubertone MV et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526-1533
3. Brinckmann J, Hunzelmann N, El Hallous E et al. (2005) Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 7: R1221-R1226
4. Cepeda EJ, Reveille JD (2004) Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 16: 723-732
5. Chizzolini C, Raschi E, Rezzonico R et al. (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46: 1602-1613
6. Chung L, Utz PJ (2004) Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 6: 156-163
7. Conrad K, Mehlhorn J (2000) Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol 123: 77-91
8. Crilly A, Hamilton J, Clark CJ et al. (2002) Analysis of transforming growth factor beta 1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61: 678-681
9. Dick T, Mierau R, Bartz-Bazzanella P et al. (2002) Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61: 121-127
10. Dodig TD, Mack KT, Cassarino DF, Clark SH (2001) Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 44: 723-727
11. Eaker EY, Kuldau JG, Verne GN et al. (1999) Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 133: 551-556
12. Fregeau DR, Leung PS, Coppel RL et al. (1988) Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 31: 386-392
13. Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17: 746-751
14. Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123: 1144-1150
15. Greidinger EL, Zang Y, Jaimes K et al. (2006) A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum 54: 661-669
16. Hénault J, Robitaille G, Senécal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54: 963-973
17. Hill MB, Phipps JL, Cartwright RJ et al. (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106: 491-497
18. Howe S, Eaker EY, Sallustio JE et al. (1994) Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 94: 761-770
19. Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48: 1363-1373
20. Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4: 99-107
21. Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ (1988) Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47: 634-641
22. Kaufman LD, Gruber BL, Marchese MJ, Seibold JR (1989) Anti-IgE autoantibodies in systemic sclerosis (scleroderma). Ann Rheum Dis 48: 201-205
23. Kuwana M, Kaburaki J, Mimori T et al. (2000) Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43: 1074-1084
24. Lee EB, Kim JY, Lee YJ et al. (2004) Transforming growth factor-beta 1 polymorphisms in Korean patients with systemic sclerosis. Tissue Antigen 63: 491-495
25. LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573-1576
26. Lunardi C, Bason C, Navone R et al. (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183-1186
27. Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22: S5-S13
28. Masi AT, Rodnan GP, Medsger TA et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590
29. Mierau R, Genth E (2002) Neue Aspekte der Autoantikörper-Diagnostik bei Kollagenosen. Z Rheumatol 61: 355-366
30. Momot T, Koch S, Hunzelmann N et al. (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50: 1561-1565
31. Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10: CR615-CR621
32. Nielen MMJ, van Schaardenburg D, Reesink HW et al. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis - A study of serial measurements in blood donors. Arthritis Rheum 50: 380-386
33. Nishijima C, Hayakawa I, Matsushita T et al. (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138: 357-363
34. Ohtsuka T, Yamakage A, Yamazaki S (2002) The polymorphism of transforming growth factor-beta1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 147: 458-463
35. Rantapää Dahlqvist S, deJong BAW, Berglin E et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48: 2741-2749
36. Reveille JD, Fischbach M, McNearney T et al. (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30: 332-346
37. Sato S, Hamaguchi Y, Hasegawa M, Takehara K (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 40: 1135-1140
38. Sato S, Hayakawa I, Hasegawa M et al. (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120: 542-547
39. Sato H, Lagan AL, Alexopoulou C et al. (2004) The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 50: 558-564
40. Senécal JL, Hénault J, Raymond Y (2005) The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 32: 1643-1649
41. Sgonc R, Gruschwitz MS, Boeck G et al. (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43: 2550-2562
42. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35: 35-42
43. Sugiura Y, Banno S, Matsumoto Y et al. (2003) Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. J Rheumatol 30: 1520-1523
44. Tan FK, Arnett FC, Antohi S et al. (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163: 1066-1072
45. Tan FK, Arnett FC, Reveille JD et al. (2000) Autoantibodies to fibrillin 1 in systemic sclerosis - Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 43: 2464-2471
46. Tsuchiya N, Kuroki K, Fujimoto M et al. (2004) Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50: 4002-4007
47. Weiner ES, Hildebrandt S, Senécal JL et al. (1991) Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. Arthritis Rheum 34: 68-77
48. Zhou X, Tan FK, Milewicz DM et al. (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype". J Immunol 175: 4555-4560